Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Mainz Biomed N.V. - Ordinary Shares
(NQ:
MYNZ
)
0.5810
-0.0375 (-6.06%)
Streaming Delayed Price
Updated: 3:59 PM EDT, May 21, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
201,515
Open
0.6235
Bid (Size)
0.5700 (1)
Ask (Size)
0.5950 (10)
Prev. Close
0.6185
Today's Range
0.5700 - 0.6505
52wk Range
0.5700 - 5.060
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Mainz Biomed Awarded Poster of Distinction at Digestive Disease Week, Positioning the Company for its Planned FDA Trial
May 20, 2024
From
Mainz BioMed NV
Via
GlobeNewswire
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
May 17, 2024
The final day of trading this week is here and we have the biggest pre-market stock movers worth watching on Friday morning!
Via
InvestorPlace
Performance
YTD
-50.34%
-50.34%
1 Month
-33.26%
-33.26%
3 Month
-42.48%
-42.48%
6 Month
-49.48%
-49.48%
1 Year
-88.14%
-88.14%
More News
Read More
Pfizer, AstraZeneca, Sanofi And Mainz Biomed To Uplevel Europe's Pharma Game
May 16, 2024
Via
Benzinga
Mainz Biomed to Present Results of Colorectal Cancer Screening Study eAArly DETECT at Digestive Disease Week 2024 in Washington, D.C.
May 07, 2024
From
Mainz BioMed NV
Via
GlobeNewswire
mRNA Is Promising A Breakthrough In Fighting Cancer
April 29, 2024
Via
Benzinga
Exposures
COVID-19
Mainz Biomed Reports Positive Topline Results from Pooled Study Evaluating Novel mRNA Biomarkers and Proprietary AI Algorithm for Integration into Pivotal FDA PMA Clinical Trial for Next Generation Colorectal Cancer Diagnostic
April 25, 2024
From
Mainz BioMed NV
Via
GlobeNewswire
The Pharmaceutical Industry Finds Itself At A Historical Crossroads
April 10, 2024
Via
Benzinga
MYNZ Stock Earnings: Mainz Biomed Beats EPS, Misses Revenue for Q4 2023
April 09, 2024
Via
InvestorPlace
Mainz Biomed Reports Full Year 2023 Financial Results
April 09, 2024
From
Mainz BioMed NV
Via
GlobeNewswire
Pharma's Post-Pandemic Story To Unlock A Cancer-Free Era
April 02, 2024
Via
Benzinga
Exposures
COVID-19
Mainz Biomed Organizes HALLO DOC! Event to Highlight Innovations in Colorectal Cancer Treatment
March 19, 2024
From
Mainz BioMed NV
Via
GlobeNewswire
Mainz Biomed: Webinar on Early Detection of Colorectal Cancer - Exploring New Laboratory Diagnostic Options
March 18, 2024
From
Mainz BioMed NV
Via
GlobeNewswire
Mainz Biomed Presents ColoAlert® at UDH Congress 2024: Leading the Way in Evidence-Based Cancer Screening Innovations
March 12, 2024
From
Mainz BioMed NV
Via
GlobeNewswire
Mainz Biomed Partners with Trusted Health Advisors to Support U.S. Go-To-Market Strategy for Next Generation Early Colorectal Cancer Diagnostic
March 05, 2024
From
Mainz BioMed NV
Via
GlobeNewswire
Gynecology Plays A Pivotal Role In Colorectal and Endometrial Cancer Screening
February 28, 2024
Via
Benzinga
Mainz Biomed to Showcase at the Gynecology Conference in Stuttgart, Germany, Strengthening Connections within the Medical Community
February 27, 2024
From
Mainz BioMed NV
Via
GlobeNewswire
Outdoing Cancer Requires Pharma To Go Beyond Merely Revolutionizing Existing Treatment
February 22, 2024
Via
Benzinga
Topics
Intellectual Property
Exposures
COVID-19
Intellectual Property
Mainz Biomed Announces Distribution Partnership with Praxisdienst for ColoAlert®
February 22, 2024
From
Mainz BioMed NV
Via
GlobeNewswire
Mainz Biomed Establishes Strategic Partnership with TomaLab to Expand Availability of ColoAlert® in Italy
February 21, 2024
From
Mainz BioMed NV
Via
GlobeNewswire
2024 Promises To Bring Pharmaceutical Breakthroughs On The Oncology Front
February 07, 2024
Via
Benzinga
Mainz Biomed Establishes Physician-Led Laboratory Expanding Service Offering for Privately Insured Patients in Germany
February 06, 2024
From
Mainz BioMed NV
Via
GlobeNewswire
2 Million Cancer Diagnoses And 600,000 Cancer Deaths Expected In 2024 – Prevention Is Key To Treatment, And Mainz Biomed Is Leading The Charge
February 02, 2024
Via
News Direct
Topics
Death
Exposures
Death
Pfizer Surprises With Profit But Revolutionizing Cancer Treatment Is Its Best Chance Of Getting Back In The Saddle
February 01, 2024
Via
Benzinga
Exposures
COVID-19
2 Million Cancer Diagnoses And 600,000 Cancer Deaths Expected In 2024 – Prevention Is Key To Treatment, And Mainz Biomed Is Leading The Charge
February 01, 2024
Via
Benzinga
Topics
Death
Exposures
Death
Mainz Biomed and TestDNA Drive CRC Innovation at the 10th Gdańsk Gastroenterology Symposium
January 11, 2024
From
Mainz BioMed NV
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.